Oxford, UK, Thursday 06 June 2020 10.00 CEST
The largest study to date on combining routine psychotherapy with digital therapeutics confirmed that adding GAIA’s deprexis significantly boosts treatment effectiveness. These results were shown over a period of six months in a sample of 340 patients with mild to moderate depression. The study showed that the adjunctive use of deprexis, on top of regular psychotherapy, produces clinically relevant and lasting effects not just on depression reduction but also on improvements in quality of life and general therapeutic progress.
Interestingly, these synergistic effects were observed independent from the therapeutic orientation of therapists, suggesting that cognitive behavior therapists as well as psychodynamic psychotherapists can expect benefit when they offer deprexis to their patients.
The results of this study are consistent with previous randomized controlled trials showing that adding deprexis to inpatient or outpatient depression therapy significantly enhances treatment effectiveness (Zwerenz et al., 2017, 2019; Berger et al., 2017). These findings reinforce our team’s continuous efforts to develop effective and scalable digital therapeutics for a broad range of clinically relevant conditions.
The study was published in the latest issue of the renowned Journal of Affective Disorders.
You can refuse the use of Google Analytics by clicking on the following link. An opt-out cookie will be set on the computer, which prevents the future collection of your data when visiting this website: Disable Google Analytics
Further information concerning the terms and conditions of use and data privacy can be found at http://www.google.com/analytics/terms/gb.html or at http://www.google.com/intl/en/analytics/privacyoverview.html.
Please note that on this website, Google Analytics code is supplemented by “gat._anonymizeIp();” to ensure an anonymized collection of IP addresses (so called IP-masking).